Beijing Konruns Pharmaceutical Co Ltd Tangible Net Worth Ratio
Beijing Konruns Pharmaceutical Co Ltd tangible net worth ratio. Beijing Konruns Pharmaceutical Co Ltd (603590) has a Tangible Net Worth Ratio of 67.2% as of March 2026. This metric is calculated by deducting intangible assets (CN¥1.15 Billion) from net assets (CN¥3.51 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Check how strategically is Beijing Konruns Pharmaceutical Co Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Beijing Konruns Pharmaceutical Co Ltd (2013–2025)
Tangible net worth ratio of Beijing Konruns Pharmaceutical Co Ltd from 2013 to 2025. This chart shows how Beijing Konruns Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 67.2%, reflecting net assets of CN¥3.51 Billion with intangible assets of CN¥1.15 Billion CNY. See Beijing Konruns Pharmaceutical Co Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Beijing Konruns Pharmaceutical Co Ltd Tangible Net Worth Ratio by Year (2013–2025)
Beijing Konruns Pharmaceutical Co Ltd tangible net worth ratio by year from 2013 to 2025. The table below presents the year-by-year Tangible Net Worth Ratio for Beijing Konruns Pharmaceutical Co Ltd from 2013 to 2025, covering 13 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see 603590 market cap overview.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 67.4% | CN¥3.50 Billion | CN¥1.14 Billion | CN¥4.09 Billion | ▼ -1.2 pp |
| 2024 | 68.6% | CN¥3.43 Billion | CN¥1.08 Billion | CN¥3.92 Billion | ▼ -1.5 pp |
| 2023 | 70.1% | CN¥3.36 Billion | CN¥1.00 Billion | CN¥3.78 Billion | ▼ -0.7 pp |
| 2022 | 70.8% | CN¥3.19 Billion | CN¥931.51 Million | CN¥3.42 Billion | ▼ -0.6 pp |
| 2021 | 71.4% | CN¥3.13 Billion | CN¥896.24 Million | CN¥3.37 Billion | ▼ -2.1 pp |
| 2020 | 73.5% | CN¥3.08 Billion | CN¥818.21 Million | CN¥3.79 Billion | ▼ -24.3 pp |
| 2019 | 97.8% | CN¥2.73 Billion | CN¥60.30 Million | CN¥3.17 Billion | ▲ +1.0 pp |
| 2018 | 96.8% | CN¥2.48 Billion | CN¥80.44 Million | CN¥2.92 Billion | ▲ +3.4 pp |
| 2017 | 93.4% | CN¥1.36 Billion | CN¥89.62 Million | CN¥1.67 Billion | ▲ +4.7 pp |
| 2016 | 88.7% | CN¥874.92 Million | CN¥98.66 Million | CN¥1.02 Billion | ▲ +4.6 pp |
| 2015 | 84.2% | CN¥683.27 Million | CN¥108.17 Million | CN¥845.80 Million | ▲ +8.3 pp |
| 2014 | 75.9% | CN¥488.02 Million | CN¥117.69 Million | CN¥665.04 Million | ▲ +14.2 pp |
| 2013 | 61.7% | CN¥313.45 Million | CN¥120.00 Million | CN¥515.13 Million | — |